Groups of mice infected intravenously with Candida albicans were treated intraperitoneally with amphotericin B, caspofungin, or fluconazole, starting at intervals before and after challenge. Survival was longest and tissue burdens were most reduced with early treatment, and survival times fell proportionately as treatment was delayed, reinforcing clinical recommendations for the earliest possible initiation of antifungal therapy.
vere illness were humanely terminated and recorded as dying on the following day. On postchallenge day 4, animals 11 and 12 from each group were humanely terminated, and C. albicans burdens were determined by viable counting of homogenates from the left kidney and the brain, which were removed aseptically. Viable count detection limits were 2.0 log 10 CFU/g for the kidney and 1.8 log 10 CFU/g for the brain. For organ homogenates that were culture-negative, a count of 0.5 log 10 below these limits was assigned for the calculation of mean burdens for the whole group.
Amphotericin B (Fungizone) for injection, fluconazole (Diflucan) for injection, and caspofungin (Cancidas) powder for injection were purchased via the local hospital pharmacy, reconstituted according to the manufacturers' directions, and diluted in sterile saline to concentrations suitable for doses of 1 mg/kg (amphotericin B and caspofungin) or 10 mg/kg (fluconazole) in volumes of approximately 100 l.
The experimental design involved administration of each of the three test agents by daily intraperitoneal (i.p.) dosing for a period of 7 days. Dosing regimens were started on days Ϫ1, 0, 1, 2, and 3 relative to the day of challenge (day 0) with 2 ϫ 10 4 CFU of C. albicans/g and on days Ϫ1, 0, 1, and 2 relative to the day of challenge with 1 ϫ 10 5 CFU of C. albicans/g. To ensure equivalent handling of all animals, i.p. injections were done for all groups from day Ϫ1 through day 10; on days before and after the 7-day period of treatment with antifungal agents, the animals were injected with saline. A control group was injected with saline from day Ϫ1 through day 10. Saline and antifungal treatments on the day of challenge (day 0) were given just prior to the i.v. inoculation.
Survival was monitored for animals 1 to 10 in each experimental group to 14 days for animals challenged with 1 ϫ 10 5 CFU/g and to 21 days for animals challenged with 2 ϫ 10 4 CFU/g. Organ burdens of C. albicans were determined for all animals at the time of their death or termination. Survival data were analyzed by Kaplan-Meier log rank tests, and mean organ burdens were calculated by Student's t test.
Challenge with 2 ؋ 10 4 CFU/g. All animals that were treated with amphotericin B or caspofungin (1 mg/kg) starting on day Ϫ1, 0, or 1 relative to the day of challenge survived to the end of the experiment (on day 21), except for one mouse in the caspofungin group, which was treated from 1 day after challenge and survived to day 13 ( Fig. 1) . When amphotericin B or caspofungin treatment began on postchallenge day 2 or 3 ( Fig.  1A and B) or fluconazole treatment began on day 1, 2, or 3 ( Fig. 1C) , the numbers of animals surviving to day 21 fell progressively.
Mean survival times for all groups of treated mice were significantly prolonged compared to those of controls, except when amphotericin B treatment began 3 days after challenge (Table 1) . However, mean survival times tended to fall, and the P value for the log rank statistic generally rose, with each day after challenge that treatment was started. Among amphotericin B-treated mice, kidney burdens at the time of termination were undetectable for all but one of the animals when treatment started on day Ϫ1, 0, 1, or 2, but they were detectable in 4 of the 10 animals whose treatment began on day 3 (Table 1) .
C. albicans-positive brain cultures were also predominantly negative for amphotericin B-treated mice, except for the group of animals whose treatment started on day 3. Mean kidney and brain burdens were significantly reduced relative to placebotreated animals in all amphotericin B-treated mice ( Table 1) . The tissue burden data for caspofungin-treated mice followed a trend similar to that for the amphotericin B-treated animals ( Table 1) . Regardless of the time at which caspofungin treatment was started, the brain and kidney burdens were significantly lower than those in placebo-treated animals. However, in the caspofungin-treated animals, the mean kidney burdens increased progressively with each day's delay of treatment after the day of challenge (Table 1) . In mice treated with fluconazole, kidney burdens remained fairly high regardless of the on June 19, 2017 by guest http://aac.asm.org/ day on which treatment started; none of the mean burdens was significantly lower than in placebo-treated mice. Brain burdens in fluconazole-treated animals were significantly reduced from control values when treatment was started up to 2 days postchallenge, but there was no reduction in brain burdens when treatment started on day 3 (Table 1) . Mean kidney and brain burdens determined on day 4 of the experiment for two animals in each treatment group were seldom significantly lower than for placebo-treated mice, although they showed a clear trend towards higher burdens with increasing delay in initiation of treatment (Table 1 ). In animals that received amphotericin B or caspofungin, the 4-day burdens were often significantly higher than the mean burdens determined at the time of death or termination of the animals ( Table 1) . A similar correlation between mean burden on day 4 and the day treatment started was seen for animals treated with fluconazole (Table 1) . However, in these animals, the kidney burdens tended to be lower on day 4 than at the time of death, while the brain burdens were higher.
Challenge with 10 5 CFU/g. A trend towards lower survival and higher tissue burdens with each day's delay in starting antifungal treatment was also evident in mice challenged with an inoculum high enough to cause rapid disseminated infection. Kaplan-Meier curves (Fig. 2) showed that very few animals treated from day Ϫ1 or 0 relative to the day of challenge failed to survive to day 14, while animals whose treatment began on day 1 showed reduced mean survival times, although they were significantly prolonged relative to placebo treatment ( Table 2 ). All placebo-treated mice and those whose fluconazole treatment started on day 2 failed to survive beyond day 3. Mean survival was slightly but not significantly prolonged among mice given amphotericin B or caspofungin starting on day 2 ( Table 2) . The mean organ burdens of C. albicans at the time of termination (Table 2) were significantly reduced when amphotericin B and caspofungin treatment began up to 1 day after challenge. In mice given fluconazole on days Ϫ1 and 0, a significant reduction in brain and kidney burdens was achieved; however, when treatment began 1 day after challenge, only the brain burdens showed significant reductions from control levels ( Table 2) . None of the antifungal agents achieved significant reductions in any organ burdens when treatment began on postchallenge day 2. The early deaths of many mice meant that the day 4 burden data were incomplete; these results are therefore not shown.
On one level, the results of this study were predictable. The later treatment of an infection is delayed, the lower the chances for successful eradication of that infection. We have now, however, systematically quantified the consequences of delaying commencement of treatment of an experimental disseminated C. albicans infection both when the infection progressed steadily (2 ϫ 10 4 CFU/g challenge) and when the infection progressed very rapidly (1 ϫ 10 5 CFU/g challenge). In both situations, all three antifungal agents tested performed well, significantly prolonging survival and, particularly in the cases of amphotericin B and caspofungin, reducing tissue burdens of fungi. However, these therapeutic effects were maximal only when mice were treated before or very soon after the time of infection.
Our treatment doses for amphotericin B and caspofungin were based on fairly uniform literature reports of efficacies in tests with C. albicans infections in immunologically intact and immunosuppressed mice (1, 2, 4, 6, 9, 17). The fluconazole dose was less easy to choose since published reports show efficacy for a wide range of doses given i.p. in various mouse models of disseminated C. albicans infection (3, 4, 7, 10, 15) , and our choice of 10 mg/kg was lower than optimal according to one pharmacokinetic study of fluconazole with mice (10) .
In clinical practice, antifungal therapy is commonly started empirically several days after antibacterial drugs have been given, since bacterial infections are the most common cause of fever (11, 13) . To the extent that data from animal experiments can be extrapolated to the clinical situation, our study shows that a wait of 3 to 4 days after onset of a fungal infection could seriously reduce the likelihood of treatment success, even when the infecting fungus is susceptible to the agent used. We consider our findings justification for considering the addition of antifungal treatment to antibacterial agents as soon as possible after the commencement of fever in a patient at risk whenever there is a possibility that the fever may be caused by a fungus rather than, or as well as, a bacterium. With agents of low toxicity, such as fluconazole and caspofungin, available for treatment of fungal infections, it should be possible to commence even empirical therapy of possible candidemias sooner rather than later. D.M.M. is supported by the University of Aberdeen. The work of our laboratory is funded by grants from several bodies, including the Wellcome Trust, BBSRC, the British Society for Antimicrobial Chemotherapy, and Merck & Co., Inc.
